KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Change in Account Payables: 2020-2024

Historic Change in Account Payables for AbCellera Biologics (ABCL) over the last 4 years, with Sep 2024 value amounting to $4.1 million.

  • AbCellera Biologics' Change in Account Payables was N/A to $4.1 million in Q3 2024 from the same period last year, while for Sep 2024 it was -$12.2 million, marking a year-over-year change of. This contributed to the annual value of -$3.2 million for FY2022, which is 31.85% up from last year.
  • Per AbCellera Biologics' latest filing, its Change in Account Payables stood at $4.1 million for Q3 2024, which was down 12.64% from $4.7 million recorded in Q2 2024.
  • In the past 5 years, AbCellera Biologics' Change in Account Payables ranged from a high of $24.3 million in Q4 2020 and a low of -$32.7 million during Q3 2022.
  • Over the past 3 years, AbCellera Biologics' median Change in Account Payables value was $2.8 million (recorded in 2022), while the average stood at -$1.9 million.
  • Per our database at Business Quant, AbCellera Biologics' Change in Account Payables crashed by 4,473.08% in 2021 and then skyrocketed by 420.40% in 2022.
  • Quarterly analysis of 5 years shows AbCellera Biologics' Change in Account Payables stood at $24.3 million in 2020, then declined by 9.66% to $21.9 million in 2021, then plummeted by 93.04% to $1.5 million in 2022, then crashed by 171.11% to -$16.3 million in 2023, then surged by 69.99% to $4.1 million in 2024.
  • Its last three reported values are $4.1 million in Q3 2024, $4.7 million for Q2 2024, and -$4.9 million during Q1 2024.